VALCHLOR® (mechlorethamine) gel is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF‑CTCL) in patients who have received prior skin-directed therapy

Prescribing VALCHLOR

VALCHLOR is exclusively available from a specialty pharmacy

VALCHLOR is a topical chemotherapeutic agent that, upon the physician’s prescription, is shipped and refilled under quality-controlled conditions by a specialty pharmacy. Pharmacy personnel are experts in the management, supervision, and delivery of prescription medications requiring special handling. The specialty pharmacy also stays in touch with your patient to answer general questions about using VALCHLOR and to help ensure receipt and proper usage and storage of the original prescription and all refills.

How to prescribe VALCHLOR

1. Complete the Prescription Enrollment Form with the following information, then fax it to VALCHLOR Support at 1-877-251-9475.

Download form
  • Patient information
  • Prescriber information
  • Prescription information
  • Patient consent

2. VALCHLOR Support will call your patient and provide:

  • Insurance verification and information on financial assistance for eligible patients
  • Resources for disease and product information
  • Prescription management and refill instructions
VALCHLOR Support professional advising VALCHLOR patient by phone

3. VALCHLOR is shipped directly to your patient.

  • VALCHLOR is supplied through a specialty pharmacy under quality-controlled conditions
  • VALCHLOR Support provides monthly reminders to your VALCHLOR patients

You can find more information on how to help patients start and stay on VALCHLOR therapy here

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VALCHLOR is contraindicated in patients with known severe hypersensitivity to mechlorethamine. Hypersensitivity reactions, including anaphylaxis, have occurred with topical formulations of mechlorethamine.

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

The most common adverse reactions (≥5%) were dermatitis (56%), pruritus (20%), bacterial skin infection (11%), skin ulceration or blistering (6%), and hyperpigmentation (5%). These reactions may be moderately severe or severe. Elderly patients aged 65 and older may be more susceptible. Depending on severity, treatment reduction, suspension, or discontinuation may be required.

DOSING AND APPLICATION

VALCHLOR is for topical dermatologic use only. Apply a thin film of gel once daily to affected areas of the skin. VALCHLOR is a cytotoxic drug and special handling and disposal procedures should be followed during use. Caregivers must wear disposable nitrile gloves when applying VALCHLOR. Patients and caregivers must wash hands thoroughly after handling or applying VALCHLOR.

To report SUSPECTED ADVERSE REACTIONS, contact Helsinn Therapeutics (U.S.), Inc., at 1-855-4-VALCHLOR (1-855-482-5245) or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Please see VALCHLOR full Prescribing Information.